SCHEMBL959784

SCHEMBL959784

CN(C)S(=O)(=O)n1ccc(Cl)n1

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TSHR P16473 1/20 0.32
PKM P14618 1/20 0.31
KDM4E B2RXH2 2/20 0.30
TNF P01375 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12128393 0.78 HTT (0.47) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL25360339 0.77 MEN1 (0.37) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL535681 0.77 HTT (0.36) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL16125118 0.77 HTT (0.33) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL3024635 0.74 SMN1; SMN2 (0.35) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL16125119 0.74 SORD (0.37) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL2158360 0.74 HTT (0.34) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL14901206 0.74 HTT (0.34) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL877521 0.73 CRBN (0.35) MEN1KMT2AHTTALDH1A1L3MBTL1
SCHEMBL4650978 0.72 SMN1; SMN2 (0.39) MEN1KMT2AHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562015-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 EP disclosed
US-20240352037-A1 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS NUVALENT, INC. 2024-10-24 US disclosed
US-12054498-B2 Heteroaromatic macrocyclic ether chemotherapeutic agents NUVALENT, INC. (US) 2024-08-06 US disclosed
WO-2024026481-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-20230107663-A1 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS NUVALENT, INC. 2023-04-06 US disclosed
EP-4146626-A2 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS Nuvalent, Inc. (US) 2023-03-15 EP disclosed
US-11542278-B1 Heteroaromatic macrocyclic ether chemotherapeutic agents NUVALENT, INC. (US) 2023-01-03 US disclosed
WO-2021226208-A2 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS NUVALENT, INC. (US) 2021-11-11 WO disclosed
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2020-05-12 US disclosed
US-20180282298-A1 PROCESS FOR THE PREPARATION OF THE 3-(3-CHLORO-1H-PYRAZOL-1-YL)PYRIDINE DOW AGROSCIENCES LLC (US) 2018-10-04 US disclosed
US-20040198984-A1 1-(3-halopyrid-2-yl)-3-substituted-5-((2,4-substituted-6-aminocarbonyl)phenylaminocarbonyl) pyrazoles insecticides FMC CORPORATION 2004-10-07 US disclosed
WO-2004067528-A1 CYANO ANTHRANILAMIDE INSECTICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-08-12 WO disclosed
US-20040102324-A1 Heterocyclic diamide invertebrate pest control agents E.I. DU PONT DE NEMOURS AND COMPANY 2004-05-27 US disclosed
EP-1416797-A1 ARTHROPODICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-05-12 EP disclosed
EP-1416796-A1 METHOD FOR CONTROLLING PARTICULAR INSECT PESTS BY APPLYING ANTHRANILAMIDE COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-05-12 EP disclosed
WO-2004011447-A2 METHOD FOR PREPARING FUSED OXAZINONES FROM ORTHO-AMINO AROMATIC CARBOXYLIC ACID AND A CARBOXYLIC ACID IN THE PRESENCE OF A SULFONYL CHLORIDE AND PYRIDINE E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-02-05 WO disclosed
EP-1373210-A1 HETEROCYCLIC DIAMIDE INVERTEBRATE PEST CONTROL AGENTS E. I. du Pont de Nemours and Company (US) 2004-01-02 EP disclosed
WO-2003015518-A1 METHOD FOR CONTROLLING PARTICULAR INSECT PESTS BY APPLYING ANTHRANILAMIDE COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-02-27 WO disclosed
WO-2003015519-A1 ARTHROPODICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-02-27 WO disclosed
WO-2002070483-A1 HETEROCYCLIC DIAMIDE INVERTEBRATE PEST CONTROL AGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282298-A1 PROCESS FOR THE PREPARATION OF THE 3-(3-CHLORO-1H-PYRAZOL-1-YL)PYRIDINE CPS1, CBR3, PDXK MEN1 2534/4885KMT2A 1547/4885HTT 2218/4885
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof TPMT, THPO, CYP11B2 MEN1 1268/4885KMT2A 4461/4885HTT 657/4885
US-20240352037-A1 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS ABCB1, CYP2C8, PAICS MEN1 1607/4885KMT2A 2069/4885HTT 391/4885
US-20040198984-A1 1-(3-halopyrid-2-yl)-3-substituted-5-((2,4-substituted-6-aminocarbonyl)phenylaminocarbonyl) pyrazoles insecticides CYP4B1, CYP1B1, CYP2E1 MEN1 4107/4885KMT2A 2856/4885HTT 3876/4885
US-20040102324-A1 Heterocyclic diamide invertebrate pest control agents DDT, DBF4, DDC MEN1 1735/4885KMT2A 1777/4885HTT 2716/4885
US-12054498-B2 Heteroaromatic macrocyclic ether chemotherapeutic agents CYP2C8, ABCB1, CYP3A43 MEN1 1170/4885KMT2A 2154/4885HTT 1190/4885
US-11542278-B1 Heteroaromatic macrocyclic ether chemotherapeutic agents CYP2C8, ABCB1, CYP3A43 MEN1 1170/4885KMT2A 2154/4885HTT 1190/4885
US-20230107663-A1 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS ABCB1, CYP2C8, PAICS MEN1 1607/4885KMT2A 2069/4885HTT 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.